Shire’s existing expertise in the treatment of rare genetic disorders has resulted in research and development deal with Santaris Pharma AS of Denmark based on the latter’s proprietary locked nucleic acid (LNA) technology and initiation of the ‘antisense’ approach to RNA-based therapeutics.